Biotech Values

[DewDiligence]

Let the speculation about the phase-2 trial design begin!

I think it’s probable that one of GENR’s phase-2 trial*s* will be large and will have a control arm (Visudyne and/or placebo), so it can serve as one of the two large, “well-controlled” trials the FDA requires for approval. This is the approach taken by Alcon with Retaane.

For added info on trial designs, see http://tinyurl.com/3fzex .

P.S. swampboots: The phase-1/2 patients are not being followed by GENR, although Dr. Quiroz might be following them for his own research.